Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B-and T-cell immunity during 13 months in consecutive patients
We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients
from a well-defined area during month 1–13 of the pandemic. Sixty patients (median age 71 …
from a well-defined area during month 1–13 of the pandemic. Sixty patients (median age 71 …
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
M Grever, L Andritsos, V Banerji, JC Barrientos, S Bhat… - Leukemia, 2021 - nature.com
Standard treatment options in classic HCL (cHCL) result in high response rates and near
normal life expectancy. However, the disease itself and the recommended standard …
normal life expectancy. However, the disease itself and the recommended standard …
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on …
A Visentin, T Chatzikonstantinou… - American journal of …, 2023 - Wiley Online Library
In this retrospective international multicenter study, we describe the clinical characteristics
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …
Occupational and personal consequences of the COVID-19 pandemic on US oncologist burnout and well-being: A study from the ASCO Clinician Well-Being Task …
FJ Hlubocky, AL Back, TD Shanafelt… - JCO Oncology …, 2021 - ascopubs.org
INTRODUCTION: The COVID-19 pandemic is an unprecedented global crisis profoundly
affecting oncology care delivery. PURPOSE: This study will describe the occupational and …
affecting oncology care delivery. PURPOSE: This study will describe the occupational and …
Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies
P Borah, S Mirgh, SK Sharma, S Bansal, A Dixit… - Blood Cells, Molecules …, 2021 - Elsevier
Background There is scarcity of data on outcome of COVID-19 in patients with hematological
malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality …
malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality …
Response to anti‐SARS‐CoV‐2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients
J Zaleska, P Kwasnik, M Paziewska… - … Journal of Cancer, 2023 - Wiley Online Library
Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients have increased
morbidity and mortality rates of COVID‐19 due to immunosuppression associated with the …
morbidity and mortality rates of COVID‐19 due to immunosuppression associated with the …
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
Vaccination against SARS-CoV-2 is considered as the most important preventive strategy
against COVID-19, but its efficacy in patients with hematological malignancies is largely …
against COVID-19, but its efficacy in patients with hematological malignancies is largely …
Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity
Novel coronavirus disease 2019 (COVID-19) severity is highly variable, with pediatric
patients typically experiencing less severe infection than adults and especially the elderly …
patients typically experiencing less severe infection than adults and especially the elderly …
Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients
M Obeid, M Suffiotti, C Pellaton, H Bouchaab… - JAMA …, 2022 - jamanetwork.com
Importance There are limited comparative data on the durability of neutralizing antibody
(nAb) responses elicited by messenger RNA (mRNA) vaccines against the SARS-CoV-2 …
(nAb) responses elicited by messenger RNA (mRNA) vaccines against the SARS-CoV-2 …
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies
Y Liu, H Lu, W Wang, Q Liu, C Zhu - Expert review of anticancer …, 2021 - Taylor & Francis
Introduction Patients with cancer are more vulnerable to COVID-19 than the general
population. Accordingly, it is necessary to identify the risk factors for death in patients with …
population. Accordingly, it is necessary to identify the risk factors for death in patients with …